TABLE 3.
Susceptibility results for 3,050 isolates of E. coli collected from hospitals in Brooklyn during a 3-month surveillance study conducted in 2009
| Antimicrobial agent | MIC |
% of isolates |
||||
|---|---|---|---|---|---|---|
| 50% | 90% | Range | Susceptible | Intermediate | Resistant | |
| Imipenem | 0.25 | 0.25 | ≤0.12-8 | 99.97 | 0.03 | 0 |
| Meropenem | ≤0.12 | ≤0.12 | ≤0.12-8 | 99.97 | 0.03 | 0% |
| Ertapenem | ≤0.12 | ≤0.12 | ≤0.12-8 | 99.7 | 0.1 | 0.2 |
| Doripenem | ≤0.06 | ≤0.06 | ≤0.06-4 | 99.8 | ||
| Ceftriaxone | ≤0.25 | 0.5 | ≤0.25->64 | 93.7 | 1.5 | 4.8 |
| Ceftazidime | ≤0.25 | 2 | ≤0.25->32 | 93.1 | 1.5 | 5.4 |
| Cefepime | ≤0.25 | ≤0.25 | ≤0.25->32 | 96.5 | 1.9 | 1.6 |
| Piperacillin-tazobactam | 2 | 4 | ≤0.5->128 | 98 | 1.0 | 1.0 |
| Ciprofloxacin | ≤0.12 | >4 | ≤0.12->4 | 67.2 | 0.4 | 32.4 |
| Trimethoprim-sulfamethoxazole | ≤0.5 | >4 | ≤0.5->4 | 67.6 | 32.4 | |
| Polymyxin B | 1 | 1 | ≤0.12->4 | 99.8 | 0.2 | |
| CB-182,804 | 2 | 4 | ≤0.12->4 | |||
| Tigecycline | 0.25 | 0.25 | 0.03-2 | 100 | ||